Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

The Your Friends & Neighbors star opened up at a fundraiser for the Women's Cancer Research Fund this week, after she was ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...

Despite breast cancer being the most common among Japanese women, the risk of developing noncancer diseases among female breast cancer survivors has not been explored in detail. Therefore, researchers ...

Pfizer stock jumped Tuesday after the S&P 500 drugmaker beat first-quarter profit expectations on the back of savvy cost-cutting measures.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...